ERBB2 and breast cancer: Five molecular BC subtypes have been extensively characterized, comprising luminal A, with the best prognosis; luminal B/human epidermal growth factor receptor-negative (HER2-); luminal B/HER2+; HER-2 enriched [2]; and finally the most aggressive triple-negative breast cancer (TNBC) subtype, which lacks targeted therapy [2].